Abbott Laboratories: Pipeline - Products - Performance - Potential - Market Research Reports

Printer Friendly

Printed from http://www.researchandmarkets.com/reports/43047

Abbott Laboratories: Pipeline - Products - Performance - Potential

Description:

Abbott has been selling pharmaceuticals for over one hundred years and has firmly established itself as one of the leading players in this market, regularly featuring among the top fifteen companies in terms of pharmaceutical revenue. Although Abbott recorded double-digit growth in both its total revenue and in its pharmaceutical segment in 2007 and 2008, the company is recovering from a particularily trying period in 2006 when overall sales growth was less than 1 per cent. The most significant development in terms of sales in 2006 was the termination of Abbott’s distribution agreement with Boehringer Ingelheim. Effective 1st January 2006, Abbott ceased to distribute not only Mobic, formerly the second largest selling product in the company’s portfolio, but also Flomax and on 31st March 2006, Abbott also ceased to market Micardis. With the loss of these products, especially Mobic, Abbott recorded its first decline in pharmaceutical sales in recent years.

The company faces further challenges in the short- to medium-term. Within our forecast period (2008-2013), only two of the company’s major products have patent protection in place, with most of the product portfolio facing declining sales. The continued success of Humira, which in 2008 saw sales exceed US$4 billion, will be key to company performance. Within the cardiovascular field, Abbott can expect strong growth from the recently-launched Niaspan and TriLipix. Also in this field, the pipeline contains Simcor which is forecast strong sales upon launch. Within virology, Kaletra is rapidly becoming the preferred treatment worldwide for HIV, benefitting from its extensive range of formulations that give it the edge over many of its competitors

Until 2008, a core feature of Abbott’s global success was its joint venture in Japan with Takeda, TAP Pharmaceuticals. This partnership provided Abbott with the infrastructure and expertise to successfully develop and distribute a number of its products in Japan, most notably its leuprolide and lansoprazole franchises, which generated US$3.1 billion for TAP in 2007. This has lead to Japan becoming Abbott’s most profitable market outside of the US. Following conclusion of the TAP joint venture, Abbott retains rights to the leuprolide franchise. Takeda takes lansoprazole, all remaining TAP commercial and support operations and the right's to TAP's pipeline. Abbott will receive payments from Takeda on current and future TAP derived products. Over the years, both companies have benefited from the establishment of TAP, gaining important access and expertise in the key Japanese and US markets. On disbanding the alliance, both companies are now in a stong position to continue independent market development.

Outside the TAP alliance, Abbott has a history of prosperous alliances and agreements with other market leaders and emerging pharmaceutical companies. Abbott will need to utilise these alliances in order to expand its limited pipeline. Within the short- to medium-term, Abbott appears to have the growth drivers to offset any losses expected, however, in the longer-term, the product portfolio needs a rapid overhaul in order for Abbott to maintain its position amongst the world’s leading pharmaceutical companies.

Contents:

EXECUTIVE SUMMARY
A detailed and comprehensive overview of current financial position, company strategy, product and pipeline analysis.

THERAPEUTIC AREA FOCUS
Key product analysis and forecasting

Inflammation
Humira (adalimumab)

Cardiovascular
Niaspan (niacin)
TriCor (fenofibrate)

Neuroscience
Depakote/Epival/Valcote (divalproex sodium)

Virology
Kaletra (lopinavir+ritonavir)

Anti-infectives
Biaxin/Klacid/Klaricid/Biclar (clarithromycin)

Anaesthetics
Sevorane/Ultane (sevoflurane)

Metabolic
Synthroid (levothyroxine sodium)

Oncology
Lupron Depot/Lucrin (leuprolide)

OPERATIONAL DATA
A wealth of background and detail
A full 5-year financial performance assessment
Key agreements
Infrastructure
Subsidiaries and joint ventures

Summary:

This Pharmaceutical company intelligence report provides a full review of the company's activities together with five-year sales forecasts for its key products. The company's financial performance is covered in-depth, from its latest results to a complete analysis of its latest full fiscal year and an outlook for the future. A section on company strategy covers mergers, acquisitions and divestitures, key agreements, products and R&D. An overview of key products and R&D is followed by a comprehensive review of the company's product portfolio and research and development pipeline by therapeutic area. In addition, supplementary appendices provide more in-depth information on financials, agreements and corporate events.

Ordering:

Order Online - visit http://www.researchandmarkets.com/reports/43047

Order by Fax - using the order form below

Order By Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.

Page 1 of 2
Printed 29/11/2009 04:07:55

Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to
646-607-1907 (from USA) or +353 1 6849977 (from Rest of World). If you have any questions please email help@researchandmarkets.net

Order information
Please verify that the product information is correct and select the format you require.


Product Name:
Abbott Laboratories: Pipeline - Products - Performance - Potential
Web Address:
http://www.researchandmarkets.com/reports/43047
Office Code:
OC8HJNPOUMUXU

Report formats
Please enter the quantity of the report format you require.

Format	Quantity	Price
Electronic		€895.00
Hard Copy		€895.00 + EUR€ 50.00 Shipping/Handling *

* Shipping/Handling is only charged once per order.

Contact information
Please enter all the information below in BLOCK CAPITALS.


	First Name:	Last Name:
	Email Address:
	Job Title:
	Organisation:
	Address:
	City:
	Postal/Zip Code:
	Country:
	Phone Number:
	Fax Number:

Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)

Page 2 of 2
Printed 29/11/2009 04:07:55

Payment information

Please indicate the payment method you would like to use by selecting the appropriate box.

Pay by Credit Card:

	American Express
	Diners Club
	Master Card
	Visa


Cardholder's Name:

Cardholder's Signature:

Expiry Date:	/

Card Number:

CVV Security Code:

Issue Date:	/ (Diners Club only)

Pay by Check:

Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.

Pay by Wire Transfer:

Please transfer funds to:


Account number:	83313083
Sort code:	98-53-30
Swift code:	ULSBIE2D
IBAN number:	IE78ULSB98533083313083
Bank Address:	Ulster Bank, 27-35 Main St, Blackrock, Co. Dublin, Ireland.

If you have a Marketing Code please enter it below:
	Marketing Code:

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)